EcoDrugPlus

Integrin Subunit Beta 8

Ensembl ID : ENSMLEG00000037210
Gene Symbol: ITGB8
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Intercellular Adhesion Molecule 1

Ensembl ID : ENSMLEG00000034670
Gene Symbol: ICAM1
4 Cross references
93 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSMLEG00000031220
Gene Symbol: IRAK4
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 5

Ensembl ID : ENSMLEG00000029971
Gene Symbol: IL5
4 Cross references
91 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 6

Ensembl ID : ENSMLEG00000034011
Gene Symbol: IL6
4 Cross references
162 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSMLEG00000013259
Gene Symbol: IDH1
4 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSMLEG00000034012
Gene Symbol: IDH2
4 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kallikrein B1

Ensembl ID : ENSMLEG00000039956
Gene Symbol: KLKB1
4 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kelch Like Ech Associated Protein 1

Ensembl ID : ENSMLEG00000036747
Gene Symbol: KEAP1
4 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinase Insert Domain Receptor

Ensembl ID : ENSMLEG00000038992
Gene Symbol: KDR
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 11

Ensembl ID : ENSMLEG00000040992
Gene Symbol: KIF11
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 5b

Ensembl ID : ENSMLEG00000008109
Gene Symbol: KIF5B
4 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).